CD39-TGFβ Conjugate Molecule Simultaneous Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint inhibitors are limited by tumor microenvironments enriched with adenosine and TGFβ, which skew T cells toward regulatory T cells and attenuate immune effector cell activation, necessitating a therapeutic agent that can antagonize CD39 and TGFβ activities for effective cancer treatment.
Innovation Solution
A conjugate molecule comprising a CD39 inhibitory portion and a TGFβ inhibitory portion, which can interfere with CD39's interaction with its substrate and TGFβ's interaction with its receptor, respectively, to simultaneously block the adenosine pathway and TGFβ signaling, thereby normalizing the tumor microenvironment and enhancing anti-tumor effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immune checkpoint inhibitors are used, then immune suppression is partially addressed, but tumor microenvironment enriched with adenosine and TGFβ still skews T cells toward regulatory T cells and attenuates immune effector cell activation
Solution Approach 1:
The patent combines CD39 inhibitory portion and TGFβ inhibitory portion into a single conjugate molecule, enabling simultaneous blockade of both adenosine-mediated suppression and TGFβ signaling pathways. This merged approach overcomes the limitation of using separate immune checkpoint inhibitors by addressing multiple immunosuppressive mechanisms concurrently within one therapeutic agent.
Solution Approach 2:
The conjugate molecule performs multiple functions: it inhibits CD39 to block adenosine production, inhibits TGFβ signaling to prevent Treg differentiation, and enhances immune effector cell activation. This multi-functional design allows a single molecule to address various aspects of tumor microenvironment immunosuppression that would require multiple separate agents.
2Ease of manufacture
If monotherapies targeting either CD39 or TGFβ alone are used, then one pathway is blocked, but synergistic anti-tumor effects are not achieved
Solution Approach 1:
The patent merges CD39 and TGFβ inhibitory functions into a single conjugate molecule, achieving synergistic anti-tumor effects that exceed the sum of individual monotherapies. This combination approach within one molecule provides enhanced efficacy while maintaining ease of administration comparable to monotherapy.
3Reliability
If CD39 and TGFβ activities are simultaneously antagonized, then synergistic anti-tumor effects are achieved, but the complexity of therapeutic agent increases
Solution Approach 1:
The patent combines multiple inhibitory functions into a single conjugate molecule structure, where the CD39 inhibitory portion and TGFβ inhibitory portion are covalently linked. This merging approach achieves synergistic efficacy while presenting as a single therapeutic agent, simplifying administration and pharmacokinetics compared to combination therapy with separate molecules.
Data Source
AI summary
Provided are conjugate molecules comprising a CD39 inhibitory portion capable of interfering interaction between CD39 and its substrate, and a TGF β inhibitory portion capable of interfering interaction between TGF β and its receptor, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.